Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;4(3):100150.
doi: 10.1016/j.dentre.2024.100150. Epub 2024 Aug 13.

Diagnostic and therapeutic potentials of extracellular vesicles for primary Sjögren's Syndrome: A review

Arash Shahsavari  1 , Fei Liu  1
Affiliations

Diagnostic and therapeutic potentials of extracellular vesicles for primary Sjögren's Syndrome: A review

Arash Shahsavari et al. Dent Rev (N Y). 2024 Sep.

Abstract

Primary Sjögren syndrome (pSS) is a chronic autoimmune disease mainly affecting salivary and lacrimal glands. The current pSS biomarkers, serum autoantibodies, are negative in many pSS patients diagnosed with histopathology changes, indicating the need of novel biomarkers. The current therapies of pSS are merely short-term symptomatic relief and can't provide effective long-term remedy. Extracellular vehicles (EVs) are nano-sized lipid bilayer-delimited particles spontaneously released by almost all types of cells and carrying various bioactive molecules to mediate inter-cellular communications. Recent studies found that EVs from salivary gland epithelial cells and immune cells play essential roles in pSS pathogenesis. Correspondingly, EVs and their cargos in plasma and saliva are promising candidate biomarkers for pSS diagnosis. Moreover, EVs from mesenchymal stem cells have shown promises to improve pSS treatment by modulating immune responses. This review summarizes recent findings in roles of EVs in pSS pathogenesis, diagnosis, and treatment of pSS, as well as related challenges and future research directions.

Keywords: Extracellular vesicle; Immune modulation; Mesenchymal stem cells; MicroRNAs; Primary Sjögren’s syndrome; Salivary diagnostics.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors have no competing interests to declare.

References

    1. Huang Y, Li R, Ye S, Lin S, Yin G, Xie Q. Recent advances in the use of exosomes in Sjögren’s syndrome. Front Immunol 2020;11. - PMC - PubMed
    1. Brito–Zerón P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE. Early diagnosis of primary Sjögren’s syndrome: EULAR–SS task force clinical recommendations. Expert Rev Clin Immunol 2016;12(2):137–56. - PubMed
    1. Hai B, Shigemoto–Kuroda T, Zhao Q, Lee RH, Liu F. Inhibitory effects of iPSC–MSCs and their extracellular vesicles on the onset of sialadenitis in a mouse model of Sjögren’s syndrome. Stem Cells Int 2018;2018. - PMC - PubMed
    1. Generali E, Costanzo A, Mainetti C, Selmi C. Cutaneous and mucosal manifestations of Sjögren’s syndrome. Clin Rev Allergy Immunol 2017;53: 357–70. - PubMed
    1. Chung A, Wilgus ML, Fishbein G, Lynch III JP. Pulmonary and bronchiolar involvement in Sjogren’s syndrome, Seminars in respiratory and critical care medicine. Thieme Med Publishers; 2019:235–54. - PubMed

LinkOut - more resources